Immutep shares encouraging trial data at SITC 2022

SITC 2022 Logo

Immutep has revealed encouraging initial clinical data from two trials investigating its lead product candidate eftilagimod alpha in non-small-cell lung cancer. 

Findings from the trials were shared at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022.  

The INSIGHT-003 trial is evaluating eftilagimod alpha as part of a triple combination therapy with standard-of-care anti-PD-1 therapy and chemotherapy in advanced NSCLC. 

The initial clinical data show that the approach is well-tolerated and provides promising early signals of therapeutic activity, with an Objective Response Rate (ORR) of 72.7% and a Disease Control Rate (DCR) of 90.9%. Notably, 81.8% of patients had a PD-L1 Tumour Proportion Score (TPS) of <50%. 

Prof Dr Salah-Eddin Al-Batran, Scientific Lead of the INSIGHT study, noted: “Efti has accumulated an excellent safety profile to date, driving its high suitability for combination with standard-of-care therapies to address areas of unmet need for cancer patients. INSIGHT-003 represents the first triple combination therapy consisting of efti plus anti-PD-1 and chemo, and we are pleased with these promising, early results.” 

The TACTI-002 PD-L1 Phase II trial is evaluating the drug in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with 1L NSCLC. 

Wade T Iams, Assistant Professor of Medicine, Vanderbilt-Ingram Cancer Center Division of Hematology/Oncology stated: “The encouraging ORR, PFS and DCR presented today at SITC build on the promise of efti, a first-in-class soluble LAG-3 protein, to uniquely engage the innate and adaptive immune system to enhance the clinical effect of pembrolizumab.  

“Responses in TACTI-002 were seen across all PD-L1 expression levels and histologic types, including in patients with PD-L1 TPS less than 50%. The deep and durable responses driven by efti plus pembrolizumab continue to be favourable with median DoR of 21.6 months.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free